HomePipelinePNB-028Colon Cancer
PNB-028
Colon Cancer
PNB-028 for the Treatment of Colon Cancer
- Molecule
- PNB-028
- Development status
- Phase 1/2a ongoing
- Therapeutic area
- Oncology
- Biological action
- CCK inhibition via the CCK-C receptor
- Therapeutic target
- Cholecystokinin Receptors, CCK-C antagonist
- Therapeutic indication
- Colon Cancer
- Same study also covers
- Pancreatic Cancer
Stage of development
-
PNB-028
Colon CancerCCK inhibition via the CCK-C receptor
- Molecule
- PNB-028
- Indication
- Colon Cancer
- Biological action
- CCK inhibition via the CCK-C receptor
- Status
- Phase 1/2a ongoing
The study below is the company document “PNB-028 for the Treatment of Pancreatic & Colon Cancers”, which covers Colon Cancer and Pancreatic Cancer together.
- Background about target
World Cancer Fact Sheets in 2008 (http://
publications. cancerresearchuk. org/ downloads/ Product/ CS_ FS_ WORLD_ A4. pdf) indicated that GI cancers affect approximately 3.2 million people worldwide with annual mortality of 0.6 million. In addition, WHO report published on February 6th 2014 indicated, that world-wide cancer incidence in the developing world will grow exponentially, if uncontrolled. Top cancers that have been forecasted to grow are pancreatic and gastric cancers, mediated by CCK receptors. Unfortunately, there is currently no targeted therapeutics available for these cancers, making them unmet medical needs. Patients suffering from these cancers undergo chemotherapy and radiation therapy, resulting in tremendous side effects. Hence, PNB-028 will potentially become the first targeted therapy for Pancreatic Cancer. - Preclinical studies:
PNB-028 is a CCK-C isoform-selective antagonist acting on the CCK3a receptor according to most recent literature. It binds to the extracellular loop on the cholecystokinin receptor. In cell-based functional assays, PNB-028 inhibited the functions of CCK irreversibly in the nanomolar range.
PNB-028 is the first irreversible CCK-C antagonist, required for the treatment of antineoplastic diseases.
PNB-028 was tested in nude mice colon and Pancreatic Cancer xenograft models. PNB-028 completely inhibited the growth of chemo-resistant MAC16 Colon Cancer tumor growth and MIAPACA Pancreatic Cancer tumor growth. While tumors in vehicle-treated animals metastasized to lungs, tumors of PNB-028-treated animals were organ confined. Vehicle-treated tumor-bearing animals lost weight and were cachectic, while body weight of PNB-028-treated animals was within the acceptable range and were not cachexic.
Interestingly, PNB-028-treated tumors demonstrated a significant reduction in various oncogenic kinases such as RSK, MAPK and others, while phosphorylation of proteins such as p53 was increased. Moreover, histology studies demonstrated that tumors that were exposed to PNB-028 had lower proliferation index as measured by Ki67.
PNB-028 was further screened in a panel of six Colon Cancer cell lines. Interestingly, all Colon Cancer cell lines expressed CCK receptors. PNB-028 significantly and robustly inhibited the growth of these Colon Cancer cell lines without affecting the growth of any normal non-cancerous cell lines. These results convincingly demonstrate the targeted nature of PNB-028 in inhibiting colon and pancreatic cancers.
- Preclinical development studies:
DMPK studies with PNB-028 indicated, that PNB-028 was highly stable in rat, dog and human liver microsomes. After 60 minutes of incubation, greater than 50%, 50% and 90%, in rats, dogs and humans, respectively, of PNB-028 still remained intact, indicating its high stability. In addition, PNB-028 was highly available in rats with >80% bioavailability and AUC of more than 1 µg hr/ml. Other studies, including CaCo2 permeability and plasma protein binding demonstrated favorable druggable properties of PNB-028. These studies were repeated twice to confirm the results.
- Synthetic chemistry:
PNB-028 synthetic scheme has only two steps and involve highly economical raw materials. PNB-028 was successfully synthesized on a large scale with purity exceeding 99.8 %. Five kilograms of PNB-028 was synthesized to conduct regulatory toxicology and safety pharmacology studies.
- Ongoing studies:
Preclinical toxicology and safety pharmacology regulatory studies in accordance to ICH guidelines are completed and a combined phase1 / 2 clinical trial was approved by the DCGI (Indian regulatory authority) for a range of doses up to 56 days in patients.
The clinical protocol of PNB-028 was approved for both cancer indications and multiple ascending doses were approved in India in patients up to a period of 56 days. This period is sufficient for proof of efficacy leading to market authorization in India.
- Intellectual property
The PNB - molecule platform, including PNB-028 and structurally related molecules are well protected with patents filed in the US, Europe, and rest of the World.
A PCT application was also filed and granted. Examination by the PTO office in Washington DC did not find any infringement issues within this series of molecules. USPTO has issued the patent on December 28, 2014.
About PNB-028
Clinical · Phase 1/2a ongoing
A targeted oncology molecule in a DCGI-approved combined Phase 1/2 trial for pancreatic and Colorectal Cancer, with Acute Pancreatitis as a further target-based indication.
PNB-028 full profileInterested in a programme?
PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.
